KR930006022A - 페넴의 결정화법 - Google Patents

페넴의 결정화법 Download PDF

Info

Publication number
KR930006022A
KR930006022A KR1019920017057A KR920017057A KR930006022A KR 930006022 A KR930006022 A KR 930006022A KR 1019920017057 A KR1019920017057 A KR 1019920017057A KR 920017057 A KR920017057 A KR 920017057A KR 930006022 A KR930006022 A KR 930006022A
Authority
KR
South Korea
Prior art keywords
crystallization method
aqueous solution
temperature
solution
less
Prior art date
Application number
KR1019920017057A
Other languages
English (en)
Inventor
마사요시 가네꼬
시게오 야부노
Original Assignee
고니시 신베이.히사나가 가쓰이찌로
니혼레다리 가부시끼가이샤
모리따 가쓰라
다께다야꾸힝고오교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고니시 신베이.히사나가 가쓰이찌로, 니혼레다리 가부시끼가이샤, 모리따 가쓰라, 다께다야꾸힝고오교 가부시끼가이샤 filed Critical 고니시 신베이.히사나가 가쓰이찌로
Publication of KR930006022A publication Critical patent/KR930006022A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

본 발명은 (1R, 5S, 6S)-2-[(6, 7-디히드로-5H-피라졸로[1, 2-a]-[1, 2, 4]-트리아졸륨-6-일)]티오-6-[(R)-1-히드록시에틸]-1-메틸-카르바페넴-3-카르복실레이트(이하, L-627로 약칭함)의 수용액을 용액의 공융온도 내지 0℃ 미만의 온도범위로 유지함을 특징으로 하는 L-627의 결정화법에 관한 것이다. 상기 방법은 결정화로 수반되는 L-627의 손실을 줄이고, 바이알 제제 제조시 공정수를 줄이며, 이들 공정을 멸균 및 분진-미함유 조건하에 용이하게 유지할수 있고, 약제를 정량적으로 정확하게 분산시킬수 있으며, 사용시 결정을 용매에 신속히 용해하는 이점을 제공한다.

Description

페넴의 결정화법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (23)

  1. (1R, 5S, 6S)-2-[(6, 7-디히드로-5H-피라졸로[1, 2-a]-[1, 2, 4]-트리아졸륨-6-일)]티오-6-[(R)-1-히드록시에틸]-1-메틸-카르바페넴-3-카르복실레이트 화합물의 수용액을 용액의 공융온도 내지 0℃ 미만의 온도범위로 유지함을 특징으로 하는, 상기 화합물의 결정화법.
  2. 제1항에 있어서, 수용액을 동결한 후 용액의 공융온도 내지 0℃ 미만의 온도범위로 유지하는 결정화법.
  3. 제1항에 있어서, 공유온도가 -10∼-2℃인 결정화법.
  4. 제1항에 있어서, 수용액을 용액의 공융온도 내지 0℃ 미만의 온도범위로 유지하는 결정화법.
  5. 제2항 또는 제4항에 있어서, 동결공정이 -40∼-10℃에서 0.5∼48시간 동안 수행되는 결정화법.
  6. 제1항에 있어서, 온도가 -6∼-1℃인 결정화법.
  7. 제6항에 있어서, 온도가 -4∼-2℃인 결정화법.
  8. 제1항에 있어서, 수용액을 용액의 공융온도 내지 0℃ 미만의 온도범위로 유지하는 시간이 0.5∼48시간인 결정화법.
  9. 제8항에 있어서, 시간이 5∼30시간인 결정화법.
  10. 제8항에 있어서, 시간이 10∼20시간인 결정화법.
  11. 제1항에 있어서, 수용액이 알칼리 금속 할라이드를 함유하는 결정화법.
  12. 제11항에 있어서, 알칼리 금속 할라이드를 함유하는 결정화법.
  13. 제11항에 있어서, 알칼리 금속 할라이드의 수용액 중의 농도가 0.1∼10%(w/w)인 결정화법.
  14. 제1항에 있어서, 수용액에 유기용매가 추가되는 결정화법.
  15. 제14항에 있어서, 유기용매의 C1-6알콜 C3-7또는 케톤인 결정화법.
  16. 제14항에 있어서, C1-6알콜이 에탄올인 결정화법.
  17. 제14항에 있어서, 유기용매의 수용액 중의 농도가 1-10%(v/v)인 결정화법.
  18. 제1항에 있어서, (1R, 5S, 6S)-2-[(6, 7-디히드로-5H-피라졸로[1, 2-a]-[1, 2, 4]-트리아졸륨-6-일)]티오-6-[(R)-1-히드록시에틸]-1-메틸-카르바페넴-3-카르복실레이트 화합물의 수용액 중의 농도가 0.5∼10%(w/w)인 결정화법.
  19. 제18항에 있어서, 농도가 1.5∼2.5%(w/w)인 결정화법.
  20. 제1항에 있어서, 수용액을 동결한 후 용액의 공융온도 내지 0℃ 미만의 온도범위로 유지한 후 동결하는 일련의 공정을 1∼15회 반복하는 결정화법.
  21. (1R, 5S, 6S)-2-[(6, 7-디히드로-5H-피라졸로[1, 2-a]-[1, 2, 4]-트리아졸륨-6-일)]티오-6-[(R)-1-히드록시에틸]-1-메틸-카르바페넴-3-카르복실레이트 화합물을 제1항에 따른 방법에 따라 바이알에서 결정화하고, 결정을 감압하에 건조시키고, 바이알을 밀폐함을 특징으로 하는, 상기 화합물의 함유하는 바이알의 제조방법.
  22. 제21항에 따른 방법으로 제조된 바이알.
  23. 제1항에 있어서, (1R, 5S, 6S)-2-[(6, 7-디히드로-5H-피라졸로[1, 2-a]-[1, 2, 4]-트리아졸륨-6-일)]티오-6-[(R)-1-히드록시에틸]-1-메틸-카르바페넴-3-카르복실레이트의 결정의 융점을 초과하지 않는 온도에서 건조공정을 수행한 다음, 결정내의 함수량을 6∼8%(w/w)로 감소시킨후, 환경온도를 25∼50℃로 유지하고 5㎜Hg이하의 감압하에 4∼40시간동안 상기 화합물의 결정내의 수분이 약2%(w/w)이하로 될 때까지건조공정을 수행하는 결정화법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920017057A 1991-09-20 1992-09-18 페넴의 결정화법 KR930006022A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24164891 1991-09-20
JP91-241648 1991-09-20

Publications (1)

Publication Number Publication Date
KR930006022A true KR930006022A (ko) 1993-04-20

Family

ID=17077445

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920017057A KR930006022A (ko) 1991-09-20 1992-09-18 페넴의 결정화법

Country Status (9)

Country Link
US (2) US5286856A (ko)
EP (1) EP0533149A1 (ko)
JP (1) JP2767171B2 (ko)
KR (1) KR930006022A (ko)
FI (1) FI924210A (ko)
IL (1) IL103218A0 (ko)
NO (2) NO923619L (ko)
TW (1) TW264475B (ko)
ZA (1) ZA927164B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101013535B1 (ko) * 2004-10-21 2011-02-14 주식회사 만도 자동차의 파워 스티어링 장치용 실린더 튜브와 피드튜브의 조립 구조물

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW264475B (ko) * 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
US6111098A (en) * 1994-05-02 2000-08-29 Shionogi & Co., Ltd. Crystal of pyrrolidylthiocarbapenem derivative, lyophilized preparation containing said crystal, and process for producing the same
AU749234B2 (en) * 1998-03-02 2002-06-20 Merck Sharp & Dohme Corp. Process for synthesizing carbapenem antibiotics
DE10300620B4 (de) * 2002-05-18 2017-04-13 Carl Zeiss Meditec Ag Trägervorrichtung für ein medizinisch-optisches Gerät
MX2009003160A (es) 2006-09-25 2009-04-06 Ptc Therapeutics Inc Formas cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol -3-il]-benzoico.
WO2009047604A1 (en) * 2007-10-08 2009-04-16 Orchid Chemicals & Pharmaceuticals Limited Process for the preparation of carbapenem antibiotic
DE102008043318A1 (de) 2008-10-30 2010-05-12 Mvg Metallverarbeitungsgesellschaft Mbh Anhängekupplung
WO2013132422A1 (en) * 2012-03-05 2013-09-12 Orchid Chemicals & Pharmaceuticals Ltd An improved process for the preparation of carbapenem antibiotic
AR091222A1 (es) 2012-05-30 2015-01-21 Meiji Seika Pharma Co Ltd INHIBIDOR DE b-LACTAMASA Y PROCESO PARA PREPARARLO
WO2014097221A1 (en) 2012-12-21 2014-06-26 Ranbaxy Laboratories Limited Process for the purification of biapenem
BR112016006246B8 (pt) 2013-09-24 2021-10-05 Meiji Seika Pharma Co Ltd Processos de produção de derivados de diazabiciclo-octano e compostos intermediários dos mesmos
EP3613740A1 (en) 2013-10-08 2020-02-26 Meiji Seika Pharma Co., Ltd. Preparation of a diazabicyclooctane derivative
JP6779787B2 (ja) 2014-12-05 2020-11-04 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ジアザビシクロオクタン誘導体の結晶及び安定な凍結乾燥製剤の製造法
CN114349772B (zh) * 2020-10-13 2022-11-25 珠海联邦制药股份有限公司 一种比阿培南粗品的精制方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029655A (en) * 1975-04-11 1977-06-14 Eli Lilly And Company Method of preparing stable sterile crystalline cephalosporins for parenteral administration
IL53427A0 (en) * 1976-11-24 1978-01-31 Lilly Co Eli Method of preparing a rapidly dissolving powder of sterile crystalline cefozolin sodium for parenteral administration
JPS6024080B2 (ja) * 1977-06-01 1985-06-11 武田薬品工業株式会社 結晶の製造法
GB1589317A (en) * 1977-11-24 1981-05-13 Lilly Co Eli Freeze drying cephalothin sodium
JPS56120615A (en) * 1980-02-27 1981-09-22 Nippon Chemiphar Co Ltd Preparation of lyophilized powder of cephalothin
US4713451A (en) * 1984-04-09 1987-12-15 Merck & Co., Inc. Crystalline dimethyliminothienamycin
IE60588B1 (en) * 1986-07-30 1994-07-27 Sumitomo Pharma Carbapenem compound in crystalline form, and its production and use
US4866171A (en) * 1987-04-11 1989-09-12 Lederle (Japan), Ltd. (1R,5S,6S)-2-[(6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazolium-6-yl)]thio-6-[R-1-hydroxyethyl]-1-methyl-carbapenum-3-carboxylate
JPS6425779A (en) * 1987-04-11 1989-01-27 Lederle Japan Ltd (1r,5s,6s)-2-substituted-thio-6-((r)-1-hydroxyethyl)-1-methyl -carbapenem-3-carboxylic acid derivative
DK168047B1 (da) * 1987-12-07 1994-01-24 Lederle Japan Ltd (1r,5s,6s)-2-substitueret thio-6-oe(r)-1-hydroxyethylaa-1-methyl-carbapenem-3-carboxylsyrederivater, fremgangsmaade til remstilling deraf, midler og praeparater indeholdende den krystallinske forbindelse samt dens anvendelse.
US5082661A (en) * 1990-09-26 1992-01-21 Elizabeth Arden Co., Division Of Conopco, Inc. Odorless cosmetic compositions in gelatin capsules
GB9021061D0 (en) * 1990-09-27 1990-11-07 Unilever Plc Encapsulating method and products containing encapsulated material
TW264475B (ko) * 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
JPH08505877A (ja) * 1993-01-29 1996-06-25 アグロン・ファーマシュウティカルズ・インコーポレーテッド 抗増殖剤としての縮合複素環式グルタミン酸誘導体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101013535B1 (ko) * 2004-10-21 2011-02-14 주식회사 만도 자동차의 파워 스티어링 장치용 실린더 튜브와 피드튜브의 조립 구조물

Also Published As

Publication number Publication date
ZA927164B (en) 1994-03-18
AU645442B2 (en) 1994-01-13
TW264475B (ko) 1995-12-01
JP2767171B2 (ja) 1998-06-18
EP0533149A1 (en) 1993-03-24
FI924210A0 (fi) 1992-09-18
NO923619L (no) 1993-03-22
FI924210A (fi) 1993-03-21
NO971332L (no) 1993-03-22
AU2459792A (en) 1993-03-25
NO971332D0 (no) 1997-03-21
US5286856A (en) 1994-02-15
NO923619D0 (no) 1992-09-17
IL103218A0 (en) 1993-02-21
US5424069A (en) 1995-06-13
JPH05271241A (ja) 1993-10-19

Similar Documents

Publication Publication Date Title
KR930006022A (ko) 페넴의 결정화법
SK403591A3 (en) 2-ranitidine hydrochloride form, method of its preparation and pharmaceutical product with its contents
ES2183874T3 (es) Cristal derivado de pirrolidylthiocarbapenem, preparado liofilizado conteniendo dicho cristal y procedimiento para su produccion.
KR101847181B1 (ko) 에테르 용매를 이용한 리튬플로로술포닐이미드의 제조방법
CA1056729A (en) Injectable amoxycillin composition
CA2404703C (en) Novel crystal form of pyrrolidylthiocarbapenem derivative
KR970027048A (ko) 안정한 결정질 테트라하이드로엽산염
AU2001261079B2 (en) Process for formulation of antibiotic compounds
AU2001261079A1 (en) Process for formulation of antibiotic compounds
KR890003775A (ko) 결정성 세파드록실 모노하이드레이트의 제조방법
KR870001071B1 (ko) 고 결정성 나트륨 세포페라존의 제조방법
US20040242865A1 (en) Process for the isolation of crystalline imipenem
JPS60255723A (ja) メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法
DE68912270D1 (de) Lyophilisiertes MDM enthaltende Zusammensetzung und Verfahren zu deren Herstellung.
CA1339021C (en) Ó-crystals of cefazolin sodium
ES2299144T3 (es) Solvato cristalino del acido de cefuroxima con acetonitrilo.
EP0039967B1 (en) Solvate of amoxicillin, process for the preparation thereof and process for the preparation of injectable preparations from this solvate
JPH0459730A (ja) セフェム系抗生物質含有凍結乾燥製剤
SU860705A3 (ru) Способ получени кристаллической формы D-конфигурации диаммониевой соли 7 - -карбокси- -( -оксифенил)ацетамидо/-7 -метокси-3-(1-метилтетразол-5-ил)-тиометил-1-оксадетиа-3-цефем-4-карбоновой кислоты
US2580364A (en) Preparation of crystalline penicillin salts
US4416874A (en) Injectable compositions of BBM-928A
JPS61172878A (ja) カルバペネム誘導体の安定な凍結乾燥製剤の製法
JPH0344329A (ja) ホスホマイシンナトリウムの凍結乾燥製剤およびその製造法
EP0381915B1 (en) Process for preparing alkali metal salts of 3,7-substituted 7-aminocephalosporanic acid derivatives.
KR950017923A (ko) 아스파탐의 결정화 방법

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid